

7 March 2016

**ANTICIPATED ACQUISITION OF THE UNITED DRUG DIVISION AND  
OTHER ASSOCIATED BUSINESSES OF UDG HEALTHCARE PLC BY  
MCKESSON DEUTSCHLAND GMBH & CO. KGAA**

**Notice of extension of the preliminary assessment period  
mentioned in section 34A(2) of the Enterprise Act 2002 (the Act)  
published pursuant to section 107(1)(ae) of the Act**

On 3 March 2016, the European Commission referred part of anticipated acquisition by McKesson Deutschland GmbH & Co. KGaA of the United Drug Division and Other Associated Businesses of UDG Healthcare Plc (**the Merger**) to the Competition and Markets Authority (**CMA**) under Article 9 of the EC Merger Regulation. Therefore, the preliminary assessment period for the CMA to decide whether to refer the Merger for a Phase 2 investigation has commenced under section 34A(2) and (4) of the Act.

On 4 March 2016, the CMA issued a notice to McKesson Deutschland GmbH & Co. KGaA (**McKesson**) under section 109 of the Act requiring the provision of certain information and documents by 5:30 pm on Monday 7 March 2016 (**the Notice**). The information and documents required have not been provided. McKesson has, therefore, failed (with or without a reasonable excuse) to comply with a requirement of a notice under section 109 of the Act.

Accordingly, the CMA has decided that, pursuant to section 34A(5) of the Act, the preliminary assessment period should be extended until McKesson provides the information and documents to the satisfaction of the CMA as required by the Notice or the CMA cancels this extension.

The extension comes into force on the date of publication of this notice.